| Year |
Citation |
Score |
| 2023 |
Furukawa N, Yang W, Chao A, Patil A, Mirando A, Pandey N, Popel A. Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth. Research Square. PMID 37886580 DOI: 10.21203/rs.3.rs-3335225/v1 |
0.322 |
|
| 2023 |
Zhang Y, Popel AS, Bazzazi H. Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. Acs Pharmacology & Translational Science. 6: 710-726. PMID 37200806 DOI: 10.1021/acsptsci.3c00008 |
0.326 |
|
| 2023 |
Lima E Silva R, Mirando AC, Tzeng SY, Green JJ, Popel AS, Pandey NB, Campochiaro PA. Anti-angiogenic collagen IV-derived peptide target engagement with αβ and αβ in ocular neovascularization models. Iscience. 26: 106078. PMID 36844452 DOI: 10.1016/j.isci.2023.106078 |
0.349 |
|
| 2022 |
Sové RJ, Verma BK, Wang H, Ho WJ, Yarchoan M, Popel AS. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. Journal For Immunotherapy of Cancer. 10. PMID 36323435 DOI: 10.1136/jitc-2022-005414 |
0.72 |
|
| 2022 |
Ruiz-Martinez A, Gong C, Wang H, Sové RJ, Mi H, Kimko H, Popel AS. Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. Plos Computational Biology. 18: e1010254. PMID 35867773 DOI: 10.1371/journal.pcbi.1010254 |
0.762 |
|
| 2021 |
Zhao C, Medeiros TX, Sové RJ, Annex BH, Popel AS. A data-driven computational model enables integrative and mechanistic characterization of dynamic macrophage polarization. Iscience. 24: 102112. PMID 33659877 DOI: 10.1016/j.isci.2021.102112 |
0.73 |
|
| 2021 |
Wang H, Ma H, Sové RJ, Emens LA, Popel AS. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. Journal For Immunotherapy of Cancer. 9. PMID 33579739 DOI: 10.1136/jitc-2020-002100 |
0.748 |
|
| 2020 |
Mirando AC, Patil A, Rafie CI, Christmas BJ, Pandey NB, Stearns V, Jaffee EM, Roussos Torres ET, Popel AS. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 9: 1760685. PMID 32923118 DOI: 10.1080/2162402X.2020.1760685 |
0.414 |
|
| 2020 |
Ma H, Wang H, Sové RJ, Wang J, Giragossian C, Popel AS. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. Journal For Immunotherapy of Cancer. 8. PMID 32859743 DOI: 10.1136/Jitc-2020-001141 |
0.755 |
|
| 2020 |
Mirando AC, Lima E Silva R, Chu Z, Campochiaro PA, Pandey NB, Popel AS. Suppression of Ocular Vascular Inflammation through Peptide-Mediated Activation of Angiopoietin-Tie2 Signaling. International Journal of Molecular Sciences. 21. PMID 32708100 DOI: 10.3390/Ijms21145142 |
0.426 |
|
| 2020 |
Sové RJ, Jafarnejad M, Zhao C, Wang H, Ma H, Popel AS. QSP-IO: A quantitative systems pharmacology toolbox for mechanistic multi-scale modeling for immuno-oncology applications. Cpt: Pharmacometrics & Systems Pharmacology. PMID 32618119 DOI: 10.1002/psp4.12546 |
0.74 |
|
| 2020 |
Ma H, Wang H, Sove RJ, Jafarnejad M, Tsai CH, Wang J, Giragossian C, Popel AS. A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor. The Aaps Journal. 22: 85. PMID 32533270 DOI: 10.1208/S12248-020-00450-3 |
0.766 |
|
| 2020 |
Malone MK, Smrekar K, Park S, Blakely B, Walter A, Nasta N, Park J, Considine M, Danilova LV, Pandey NB, Fertig EJ, Popel AS, Jin K. Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy. Cancer Biology & Therapy. 1-10. PMID 32213106 DOI: 10.1080/15384047.2020.1739484 |
0.395 |
|
| 2020 |
Wang H, Sové RJ, Jafarnejad M, Rahmeh S, Jaffee EM, Stearns V, Torres ETR, Connolly RM, Popel AS. Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Frontiers in Bioengineering and Biotechnology. 8: 141. PMID 32158754 DOI: 10.3389/Fbioe.2020.00141 |
0.774 |
|
| 2020 |
Popel AS. Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model. Proceedings of the National Academy of Sciences of the United States of America. 117: 4447-4449. PMID 32102915 DOI: 10.1073/Pnas.2001050117 |
0.373 |
|
| 2020 |
Mirando AC, Patil A, Rafie CI, Christmas BJ, Pandey NB, Stearns V, Jaffee EM, Roussos Torres ET, Popel AS. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide Oncoimmunology. 9: 1760685. DOI: 10.1080/2162402x.2020.1760685 |
0.313 |
|
| 2019 |
Zhao C, Mirando AC, Sové RJ, Medeiros TX, Annex BH, Popel AS. A mechanistic integrative computational model of macrophage polarization: Implications in human pathophysiology. Plos Computational Biology. 15: e1007468. PMID 31738746 DOI: 10.1371/Journal.Pcbi.1007468 |
0.742 |
|
| 2019 |
Zhang Y, Kontos CD, Annex BH, Popel AS. Angiopoietin-Tie Signaling Pathway in Endothelial Cells: A Computational Model. Iscience. 20: 497-511. PMID 31655061 DOI: 10.1016/J.Isci.2019.10.006 |
0.397 |
|
| 2019 |
Jafarnejad M, Sové RJ, Danilova L, Mirando AC, Zhang Y, Yarchoan M, Tran PT, Pandey NB, Fertig EJ, Popel AS. Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. Npj Systems Biology and Applications. 5: 29. PMID 31452933 DOI: 10.1038/s41540-019-0107-2 |
0.747 |
|
| 2019 |
Milberg O, Gong C, Jafarnejad M, Bartelink IH, Wang B, Vicini P, Narwal R, Roskos L, Popel AS. A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade. Scientific Reports. 9: 11286. PMID 31375756 DOI: 10.1038/S41598-019-47802-4 |
0.314 |
|
| 2019 |
Kim J, Lima E Silva R, Shmueli RB, Mirando AC, Tzeng SY, Pandey NB, Ben-Akiva E, Popel AS, Campochiaro PA, Green JJ. Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization. Acta Biomaterialia. PMID 31374338 DOI: 10.1016/J.Actbio.2019.07.054 |
0.379 |
|
| 2019 |
Jafarnejad M, Gong C, Gabrielson E, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Popel AS. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. The Aaps Journal. 21: 79. PMID 31236847 DOI: 10.1208/S12248-019-0350-X |
0.349 |
|
| 2019 |
Wang H, Milberg O, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Santa-Maria CA, Popel AS. simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. Royal Society Open Science. 6: 190366. PMID 31218069 DOI: 10.1098/Rsos.190366 |
0.345 |
|
| 2019 |
Stamatelos SK, Bhargava A, Kim E, Popel AS, Pathak AP. Tumor Ensemble-Based Modeling and Visualization of Emergent Angiogenic Heterogeneity in Breast Cancer. Scientific Reports. 9: 5276. PMID 30918274 DOI: 10.1038/S41598-019-40888-W |
0.342 |
|
| 2019 |
Mirando AC, Shen J, Lima E Silva R, Chu Z, Sass N, Lorenc VE, Green JJ, Campochiaro PA, Popel AS, Pandey NB. A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2-Tie2 signaling. Jci Insight. PMID 30668550 DOI: 10.1172/Jci.Insight.122043 |
0.438 |
|
| 2018 |
Gong C, Anders RA, Zhu Q, Taube JM, Green B, Cheng W, Bartelink IH, Vicini P, Wang B, Popel AS. Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. Frontiers in Oncology. 8: 649. PMID 30666298 DOI: 10.3389/Fonc.2018.00649 |
0.33 |
|
| 2018 |
Zhang Y, Bazzazi H, Lima E Silva R, Pandey NB, Green JJ, Campochiaro PA, Popel AS. Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection. Investigative Ophthalmology & Visual Science. 59: 5266-5276. PMID 30383198 DOI: 10.1167/Iovs.17-23632 |
0.343 |
|
| 2018 |
Bazzazi H, Zhang Y, Jafarnejad M, Popel AS. Computational modeling of synergistic interaction between αVβ3 integrin and VEGFR2 in endothelial cells: implications for the mechanism of action of angiogenesis-modulating integrin-binding peptides. Journal of Theoretical Biology. PMID 30036530 DOI: 10.1016/J.Jtbi.2018.06.029 |
0.468 |
|
| 2018 |
Bazzazi H, Zhang Y, Jafarnejad M, Isenberg JS, Annex BH, Popel AS. Computer Simulation of TSP1 Inhibition of VEGF-Akt-eNOS: An Angiogenesis Triple Threat. Frontiers in Physiology. 9: 644. PMID 29899706 DOI: 10.3389/Fphys.2018.00644 |
0.398 |
|
| 2018 |
Jin K, Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Research : Bcr. 20: 54. PMID 29898755 DOI: 10.1186/S13058-018-0981-3 |
0.396 |
|
| 2018 |
Norton KA, Jin K, Popel AS. Modeling triple-negative breast cancer heterogeneity: effects of stromal macrophages, fibroblasts and tumor vasculature. Journal of Theoretical Biology. PMID 29750999 DOI: 10.1016/J.Jtbi.2018.05.003 |
0.395 |
|
| 2018 |
Zhao C, Isenberg JS, Popel AS. Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions. Journal of Cellular and Molecular Medicine. PMID 29441713 DOI: 10.1111/Jcmm.13565 |
0.39 |
|
| 2018 |
Bressler EM, Kim J, Shmueli RB, Mirando AC, Bazzazi H, Lee E, Popel AS, Pandey NB, Green JJ. Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells. Journal of Biomedical Materials Research. Part A. PMID 29424479 DOI: 10.1002/Jbm.A.36360 |
0.717 |
|
| 2017 |
Barbhuiya MA, Mirando AC, Simons BW, Lemtiri-Chlieh G, Green JJ, Popel AS, Pandey NB, Tran PT. Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. Oncotarget. 8: 101520-101534. PMID 29254183 DOI: 10.18632/Oncotarget.21148 |
0.359 |
|
| 2017 |
Jin K, Pandey NB, Popel AS. Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. Oncotarget. 8: 60210-60222. PMID 28947965 DOI: 10.18632/Oncotarget.19417 |
0.366 |
|
| 2017 |
Gong C, Milberg O, Wang B, Vicini P, Narwal R, Roskos L, Popel AS. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. Journal of the Royal Society, Interface. 14. PMID 28931635 DOI: 10.1098/Rsif.2017.0320 |
0.331 |
|
| 2017 |
Norton KA, Wallace T, Pandey NB, Popel AS. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia. Bmc Systems Biology. 11: 68. PMID 28693495 DOI: 10.1186/S12918-017-0445-X |
0.353 |
|
| 2017 |
Bazzazi H, Isenberg JS, Popel AS. Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation. Frontiers in Physiology. 8: 48. PMID 28220078 DOI: 10.3389/Fphys.2017.00048 |
0.375 |
|
| 2017 |
Bazzazi H, Popel AS. Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells. Plos Computational Biology. 13: e1005332. PMID 28178265 DOI: 10.1371/Journal.Pcbi.1005332 |
0.39 |
|
| 2017 |
Lima E Silva R, Kanan Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, Campochiaro PA. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Science Translational Medicine. 9. PMID 28100839 DOI: 10.1126/Scitranslmed.Aai8030 |
0.448 |
|
| 2017 |
Zhao C, Isenberg JS, Popel AS. Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model. Plos Computational Biology. 13: e1005272. PMID 28045898 DOI: 10.1371/Journal.Pcbi.1005272 |
0.385 |
|
| 2017 |
Milberg O, Gong C, Wang B, Vicini P, Narwal R, Roskos L, Popel A. Abstract 4531: Systems pharmacology to predict cellular biomarkers and optimize mono- and combination-therapy regimens: Focusing on immune checkpoint targets PD-1, PD-L1 and CTLA-4 Cancer Research. 77: 4531-4531. DOI: 10.1158/1538-7445.Am2017-4531 |
0.349 |
|
| 2017 |
Barbhuiya MA, Mirando AC, Simons BW, Lemtiri-Chlieh G, Green JJ, Popel AS, Pandey NB, Tran PT. Abstract 3201: Therapeutic potential of anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma Cancer Research. 77: 3201-3201. DOI: 10.1158/1538-7445.Am2017-3201 |
0.373 |
|
| 2016 |
Dore-Savard L, Lee E, Kakkad S, Popel AS, Bhujwalla ZM. The Angiogenic Secretome in VEGF overexpressing Breast Cancer Xenografts. Scientific Reports. 6: 39460. PMID 27995973 DOI: 10.1038/Srep39460 |
0.732 |
|
| 2016 |
Kim J, Mirando AC, Popel AS, Green JJ. Gene delivery nanoparticles to modulate angiogenesis. Advanced Drug Delivery Reviews. PMID 27913120 DOI: 10.1016/J.Addr.2016.11.003 |
0.301 |
|
| 2016 |
Chu LH, Ganta VC, Choi MH, Chen G, Finley SD, Annex BH, Popel AS. A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF165b in peripheral arterial disease in human and mouse. Scientific Reports. 6: 37030. PMID 27853189 DOI: 10.1038/Srep37030 |
0.416 |
|
| 2016 |
Norton KA, Popel AS. Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis. Scientific Reports. 6: 36992. PMID 27841344 DOI: 10.1038/Srep36992 |
0.452 |
|
| 2016 |
Noren DP, Chou WH, Lee SH, Qutub AA, Warmflash A, Wagner DS, Popel AS, Levchenko A. Endothelial cells decode VEGF-mediated Ca2+ signaling patterns to produce distinct functional responses. Science Signaling. 9: ra20. PMID 26905425 DOI: 10.1126/Scisignal.Aad3188 |
0.37 |
|
| 2016 |
Jin K, Pandey NB, Popel AS. Abstract 4084: Crosstalk between TNBC and stromal components via secreted factors enhances cell motility that can be attenuated by a CXCR1 inhibitor Cancer Research. 76: 4084-4084. DOI: 10.1158/1538-7445.Am2016-4084 |
0.387 |
|
| 2016 |
Dore-Savard L, Bharti SK, Popel AS, Bhujwalla ZM. Abstract 3370: Metabolic profiling of the tumor interstitial fluid using 1H MRS: contribution of breast cancer subtypes and VEGF overexpression Cancer Research. 76: 3370-3370. DOI: 10.1158/1538-7445.Am2016-3370 |
0.435 |
|
| 2015 |
Zhao C, Popel AS. Computational Model of MicroRNA Control of HIF-VEGF Pathway: Insights into the Pathophysiology of Ischemic Vascular Disease and Cancer. Plos Computational Biology. 11: e1004612. PMID 26588727 DOI: 10.1371/Journal.Pcbi.1004612 |
0.374 |
|
| 2015 |
Fertig EJ, Lee E, Pandey NB, Popel AS. Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. Scientific Reports. 5: 12133. PMID 26173622 DOI: 10.1038/Srep12133 |
0.695 |
|
| 2015 |
Lee E, Pandey NB, Popel AS. Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment. Expert Reviews in Molecular Medicine. 17: e3. PMID 25634527 DOI: 10.1017/Erm.2015.2 |
0.727 |
|
| 2015 |
Kim E, Lee E, Plummer C, Gil S, Popel AS, Pathak AP. Vasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model. Angiogenesis. 18: 125-36. PMID 25408417 DOI: 10.1007/S10456-014-9450-5 |
0.739 |
|
| 2015 |
Finley SD, Chu LH, Popel AS. Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discovery Today. 20: 187-97. PMID 25286370 DOI: 10.1016/J.Drudis.2014.09.026 |
0.444 |
|
| 2015 |
Dore-Savard L, Lee E, Popel AS, Bhujwalla ZM. Abstract 4172: Differential angiogenesis-related cytokines release in tumor interstitial fluid and plasma in ER-positive and triple-negative breast cancers overexpressing VEGF Cancer Research. 75: 4172-4172. DOI: 10.1158/1538-7445.Am2015-4172 |
0.71 |
|
| 2014 |
Lee E, Lee SJ, Koskimaki JE, Han Z, Pandey NB, Popel AS. Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Scientific Reports. 4: 7139. PMID 25409905 DOI: 10.1038/Srep07139 |
0.824 |
|
| 2014 |
Rosca EV, Penet MF, Mori N, Koskimaki JE, Lee E, Pandey NB, Bhujwalla ZM, Popel AS. A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer. Plos One. 9: e111901. PMID 25384034 DOI: 10.1371/Journal.Pone.0111901 |
0.825 |
|
| 2014 |
Chu LH, Lee E, Bader JS, Popel AS. Angiogenesis interactome and time course microarray data reveal the distinct activation patterns in endothelial cells. Plos One. 9: e110871. PMID 25329517 DOI: 10.1371/Journal.Pone.0110871 |
0.728 |
|
| 2014 |
Norton KA, Han Z, Popel AS, Pandey NB. Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells. Oncotargets and Therapy. 7: 1571-82. PMID 25228815 DOI: 10.2147/Ott.S65055 |
0.443 |
|
| 2014 |
Norton KA, Popel AS. An agent-based model of cancer stem cell initiated avascular tumour growth and metastasis: the effect of seeding frequency and location. Journal of the Royal Society, Interface / the Royal Society. 11: 20140640. PMID 25185580 DOI: 10.1098/Rsif.2014.0640 |
0.338 |
|
| 2014 |
Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nature Communications. 5: 4715. PMID 25178650 DOI: 10.1038/Ncomms5715 |
0.771 |
|
| 2014 |
Lee E, Pandey NB, Popel AS. Lymphatic endothelial cells support tumor growth in breast cancer. Scientific Reports. 4: 5853. PMID 25068296 DOI: 10.1038/Srep05853 |
0.723 |
|
| 2014 |
Imoukhuede PI, Popel AS. Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Medicine. 3: 225-44. PMID 24449499 DOI: 10.1002/Cam4.188 |
0.435 |
|
| 2014 |
Stamatelos SK, Kim E, Pathak AP, Popel AS. A bioimage informatics based reconstruction of breast tumor microvasculature with computational blood flow predictions. Microvascular Research. 91: 8-21. PMID 24342178 DOI: 10.1016/J.Mvr.2013.12.003 |
0.359 |
|
| 2014 |
Vempati P, Popel AS, Mac Gabhann F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine & Growth Factor Reviews. 25: 1-19. PMID 24332926 DOI: 10.1016/J.Cytogfr.2013.11.002 |
0.706 |
|
| 2014 |
Logsdon EA, Finley SD, Popel AS, Mac Gabhann F. A systems biology view of blood vessel growth and remodelling. Journal of Cellular and Molecular Medicine. 18: 1491-508. PMID 24237862 DOI: 10.1111/Jcmm.12164 |
0.679 |
|
| 2014 |
Lee E, Pandey NB, Popel AS. Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model. Clinical & Experimental Metastasis. 31: 67-79. PMID 23963763 DOI: 10.1007/S10585-013-9610-9 |
0.702 |
|
| 2014 |
Dore-Savard L, Lee E, Popel AS, Bhujwalla ZM. Abstract 3001: Angiogenesis-related cytokine secretion pattern in tumor interstitial fluid and its relationship with VEGF expression and metastatic profile Cancer Research. 74: 3001-3001. DOI: 10.1158/1538-7445.Am2014-3001 |
0.742 |
|
| 2013 |
Tan WH, Popel AS, Mac Gabhann F. Computational model of VEGFR2 pathway to ERK activation and modulation through receptor trafficking. Cellular Signalling. 25: 2496-510. PMID 23993967 DOI: 10.1016/J.Cellsig.2013.08.015 |
0.709 |
|
| 2013 |
Finley SD, Dhar M, Popel AS. Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Frontiers in Oncology. 3: 196. PMID 23908970 DOI: 10.3389/Fonc.2013.00196 |
0.479 |
|
| 2013 |
Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, Campochiaro PA, Green JJ. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials. 34: 7544-51. PMID 23849876 DOI: 10.1016/J.Biomaterials.2013.06.044 |
0.779 |
|
| 2013 |
Tan WH, Popel AS, Mac Gabhann F. Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation. Plos One. 8: e67438. PMID 23805312 DOI: 10.1371/Journal.Pone.0067438 |
0.69 |
|
| 2013 |
Finley SD, Popel AS. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. Journal of the National Cancer Institute. 105: 802-11. PMID 23670728 DOI: 10.1093/Jnci/Djt093 |
0.465 |
|
| 2013 |
Lee E, Koskimaki JE, Pandey NB, Popel AS. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia (New York, N.Y.). 15: 112-24. PMID 23441126 DOI: 10.1593/Neo.121638 |
0.828 |
|
| 2013 |
Imoukhuede PI, Dokun AO, Annex BH, Popel AS. Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. American Journal of Physiology. Heart and Circulatory Physiology. 304: H1085-93. PMID 23376830 DOI: 10.1152/Ajpheart.00514.2012 |
0.4 |
|
| 2013 |
Koskimaki JE, Lee E, Chen W, Rivera CG, Rosca EV, Pandey NB, Popel AS. Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Angiogenesis. 16: 159-70. PMID 23053781 DOI: 10.1007/S10456-012-9308-7 |
0.819 |
|
| 2013 |
Lee E, Pandey N, Popel A. Abstract B27: Lymphatic endothelium promotes angiogenesis, tumor growth, and metastasis in breast cancer Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B27 |
0.736 |
|
| 2012 |
Liu G, Mac Gabhann F, Popel AS. Effects of fiber type and size on the heterogeneity of oxygen distribution in exercising skeletal muscle. Plos One. 7: e44375. PMID 23028531 DOI: 10.1371/Journal.Pone.0044375 |
0.608 |
|
| 2012 |
Imoukhuede PI, Popel AS. Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. Plos One. 7: e44791. PMID 22984559 DOI: 10.1371/Journal.Pone.0044791 |
0.414 |
|
| 2012 |
Chu LH, Rivera CG, Popel AS, Bader JS. Constructing the angiome: a global angiogenesis protein interaction network. Physiological Genomics. 44: 915-24. PMID 22911453 DOI: 10.1152/Physiolgenomics.00181.2011 |
0.346 |
|
| 2012 |
Kim E, Stamatelos S, Cebulla J, Bhujwalla ZM, Popel AS, Pathak AP. Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Annals of Biomedical Engineering. 40: 2425-41. PMID 22565817 DOI: 10.1007/S10439-012-0585-5 |
0.365 |
|
| 2012 |
Finley SD, Popel AS. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. The Aaps Journal. 14: 500-9. PMID 22547351 DOI: 10.1208/S12248-012-9363-4 |
0.464 |
|
| 2012 |
Koskimaki JE, Rosca EV, Rivera CG, Lee E, Chen W, Pandey NB, Popel AS. Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. Translational Oncology. 5: 92-7. PMID 22496925 DOI: 10.1593/Tlo.11244 |
0.819 |
|
| 2012 |
Rosca EV, Lal B, Koskimaki JE, Popel AS, Laterra J. Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth. Anti-Cancer Drugs. 23: 706-12. PMID 22495619 DOI: 10.1097/Cad.0B013E3283531041 |
0.795 |
|
| 2012 |
Rosca EV, Koskimaki JE, Pandey NB, Tamiz AP, Popel AS. Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides. Chemical Biology & Drug Design. 80: 27-37. PMID 22405100 DOI: 10.1111/J.1747-0285.2012.01376.X |
0.783 |
|
| 2012 |
Stefanini MO, Qutub AA, Mac Gabhann F, Popel AS. Computational models of VEGF-associated angiogenic processes in cancer. Mathematical Medicine and Biology : a Journal of the Ima. 29: 85-94. PMID 21266494 DOI: 10.1093/Imammb/Dqq025 |
0.71 |
|
| 2011 |
Finley SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. Bmc Systems Biology. 5: 193. PMID 22104283 DOI: 10.1186/1752-0509-5-193 |
0.48 |
|
| 2011 |
Yen P, Finley SD, Engel-Stefanini MO, Popel AS. A two-compartment model of VEGF distribution in the mouse. Plos One. 6: e27514. PMID 22087332 DOI: 10.1371/Journal.Pone.0027514 |
0.452 |
|
| 2011 |
Rivera CG, Mellberg S, Claesson-Welsh L, Bader JS, Popel AS. Analysis of VEGF--a regulated gene expression in endothelial cells to identify genes linked to angiogenesis. Plos One. 6: e24887. PMID 21931866 DOI: 10.1371/Journal.Pone.0024887 |
0.439 |
|
| 2011 |
Lee E, Rosca EV, Pandey NB, Popel AS. Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. The International Journal of Biochemistry & Cell Biology. 43: 1812-21. PMID 21920451 DOI: 10.1016/J.Biocel.2011.08.020 |
0.756 |
|
| 2011 |
Rosca EV, Koskimaki JE, Pandey NB, Wolff AC, Popel AS. Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biology & Therapy. 12: 808-17. PMID 21878750 DOI: 10.4161/Cbt.12.9.17677 |
0.815 |
|
| 2011 |
Rivera CG, Rosca EV, Pandey NB, Koskimaki JE, Bader JS, Popel AS. Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. Journal of Medicinal Chemistry. 54: 6492-500. PMID 21866962 DOI: 10.1021/Jm200114F |
0.805 |
|
| 2011 |
Rivera CG, Bader JS, Popel AS. Angiogenesis-associated crosstalk between collagens, CXC chemokines, and thrombospondin domain-containing proteins. Annals of Biomedical Engineering. 39: 2213-22. PMID 21590489 DOI: 10.1007/S10439-011-0325-2 |
0.366 |
|
| 2011 |
Vempati P, Popel AS, Mac Gabhann F. Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. Bmc Systems Biology. 5: 59. PMID 21535871 DOI: 10.1186/1752-0509-5-59 |
0.696 |
|
| 2011 |
Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS. Anti-angiogenic peptides for cancer therapeutics. Current Pharmaceutical Biotechnology. 12: 1101-16. PMID 21470139 DOI: 10.2174/138920111796117300 |
0.792 |
|
| 2011 |
Liu G, Qutub AA, Vempati P, Mac Gabhann F, Popel AS. Module-based multiscale simulation of angiogenesis in skeletal muscle. Theoretical Biology & Medical Modelling. 8: 6. PMID 21463529 DOI: 10.1186/1742-4682-8-6 |
0.669 |
|
| 2011 |
Imoukhuede PI, Popel AS. Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Experimental Cell Research. 317: 955-65. PMID 21185287 DOI: 10.1016/J.Yexcr.2010.12.014 |
0.408 |
|
| 2011 |
Waters SL, Alastruey J, Beard DA, Bovendeerd PH, Davies PF, Jayaraman G, Jensen OE, Lee J, Parker KH, Popel AS, Secomb TW, Siebes M, Sherwin SJ, Shipley RJ, Smith NP, et al. Theoretical models for coronary vascular biomechanics: progress & challenges. Progress in Biophysics and Molecular Biology. 104: 49-76. PMID 21040741 DOI: 10.1016/J.Pbiomolbio.2010.10.001 |
0.344 |
|
| 2011 |
Rosca EV, Penet M, Koskimaki JE, Pandey NB, Bhujwalla ZM, Popel AS. Abstract 4267: Biomimetic anti-angiogenic peptide as therapeutic agent for breast cancer Cancer Research. 71: 4267-4267. DOI: 10.1158/1538-7445.Am2011-4267 |
0.81 |
|
| 2010 |
Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Research. 70: 9886-94. PMID 21118974 DOI: 10.1158/0008-5472.Can-10-1419 |
0.726 |
|
| 2010 |
Fedosov DA, Caswell B, Popel AS, Karniadakis GE. Blood flow and cell-free layer in microvessels. Microcirculation (New York, N.Y. : 1994). 17: 615-28. PMID 21044216 DOI: 10.1111/J.1549-8719.2010.00056.X |
0.309 |
|
| 2010 |
Mac Gabhann F, Qutub AA, Annex BH, Popel AS. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews. Systems Biology and Medicine. 2: 694-707. PMID 20890966 DOI: 10.1002/Wsbm.92 |
0.703 |
|
| 2010 |
Mac Gabhann F, Annex BH, Popel AS. Gene therapy from the perspective of systems biology. Current Opinion in Molecular Therapeutics. 12: 570-7. PMID 20886389 |
0.609 |
|
| 2010 |
Vempati P, Mac Gabhann F, Popel AS. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. Plos One. 5: e11860. PMID 20686621 DOI: 10.1371/Journal.Pone.0011860 |
0.688 |
|
| 2010 |
Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. American Journal of Physiology. Heart and Circulatory Physiology. 298: H2174-91. PMID 20382861 DOI: 10.1152/Ajpheart.00365.2009 |
0.713 |
|
| 2010 |
Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. Bmc Cancer. 10: 29. PMID 20122172 DOI: 10.1186/1471-2407-10-29 |
0.827 |
|
| 2010 |
Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. Journal of Cellular and Molecular Medicine. 14: 528-52. PMID 19840194 DOI: 10.1111/J.1582-4934.2009.00941.X |
0.72 |
|
| 2010 |
Rosca EV, Koskimaki JE, Popel AS. Abstract 1365: Novel anti-angiogenic peptides as potential therapeutic agents in combination with chemotherapy for breast cancer Cancer Research. 70: 1365-1365. DOI: 10.1158/1538-7445.Am10-1365 |
0.815 |
|
| 2009 |
Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. Plos Computational Biology. 5: e1000622. PMID 20041209 DOI: 10.1371/Journal.Pcbi.1000622 |
0.702 |
|
| 2009 |
Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT, Raman V, Bhujwalla ZM, Popel AS. Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (New York, N.Y.). 11: 1285-91. PMID 20019836 DOI: 10.1593/Neo.09620 |
0.831 |
|
| 2009 |
Wu FT, Stefanini MO, Mac Gabhann F, Popel AS. Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models. Methods in Enzymology. 467: 461-97. PMID 19897104 DOI: 10.1016/S0076-6879(09)67018-X |
0.433 |
|
| 2009 |
Chen K, Popel AS. Nitric oxide production pathways in erythrocytes and plasma. Biorheology. 46: 107-19. PMID 19458414 DOI: 10.3233/Bir-2009-0531 |
0.324 |
|
| 2009 |
Wu FT, Stefanini MO, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. Plos One. 4: e5108. PMID 19352513 DOI: 10.1371/Journal.Pone.0005108 |
0.715 |
|
| 2009 |
Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiological Genomics. 38: 29-41. PMID 19351908 DOI: 10.1152/Physiolgenomics.00031.2009 |
0.71 |
|
| 2009 |
Qutub AA, Mac Gabhann F, Karagiannis ED, Vempati P, Popel AS. Multiscale models of angiogenesis. Ieee Engineering in Medicine and Biology Magazine : the Quarterly Magazine of the Engineering in Medicine & Biology Society. 28: 14-31. PMID 19349248 DOI: 10.1109/Memb.2009.931791 |
0.797 |
|
| 2009 |
Chen K, Pittman RN, Popel AS. Hemorrhagic shock and nitric oxide release from erythrocytic nitric oxide synthase: a quantitative analysis. Microvascular Research. 78: 107-18. PMID 19285090 DOI: 10.1016/J.Mvr.2009.02.009 |
0.342 |
|
| 2009 |
Cano Mdel V, Karagiannis ED, Soliman M, Bakir B, Zhuang W, Popel AS, Gehlbach PL. A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization. Investigative Ophthalmology & Visual Science. 50: 3840-5. PMID 19279315 DOI: 10.1167/Iovs.08-2607 |
0.775 |
|
| 2009 |
Qutub AA, Popel AS. Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. Bmc Systems Biology. 3: 13. PMID 19171061 DOI: 10.1186/1752-0509-3-13 |
0.451 |
|
| 2008 |
Karagiannis ED, Popel AS. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proceedings of the National Academy of Sciences of the United States of America. 105: 13775-80. PMID 18780781 DOI: 10.1073/Pnas.0803241105 |
0.779 |
|
| 2008 |
Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. Bmc Systems Biology. 2: 77. PMID 18713470 DOI: 10.1186/1752-0509-2-77 |
0.708 |
|
| 2008 |
Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation (New York, N.Y. : 1994). 15: 715-38. PMID 18608994 DOI: 10.1080/10739680802095964 |
0.686 |
|
| 2008 |
Qutub AA, Popel AS. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Molecular and Cellular Biology. 28: 5106-19. PMID 18559422 DOI: 10.1128/Mcb.00060-08 |
0.341 |
|
| 2008 |
Demetriades AM, Deering T, Liu H, Lu L, Gehlbach P, Packer JD, Mac Gabhann F, Popel AS, Wei LL, Campochiaro PA. Trans-scleral delivery of antiangiogenic proteins. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 24: 70-9. PMID 18370877 DOI: 10.1089/Jop.2007.0061 |
0.602 |
|
| 2008 |
Chen K, Pittman RN, Popel AS. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. Antioxidants & Redox Signaling. 10: 1185-98. PMID 18331202 DOI: 10.1089/Ars.2007.1959 |
0.36 |
|
| 2008 |
Karagiannis ED, Popel AS. Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines. Journal of Cellular Biochemistry. 104: 1356-63. PMID 18307172 DOI: 10.1002/Jcb.21712 |
0.784 |
|
| 2008 |
Chen K, Piknova B, Pittman RN, Schechter AN, Popel AS. Nitric oxide from nitrite reduction by hemoglobin in the plasma and erythrocytes. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 18: 47-60. PMID 17964300 DOI: 10.1016/J.Niox.2007.09.088 |
0.338 |
|
| 2007 |
Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. British Journal of Cancer. 97: 978-85. PMID 17912242 DOI: 10.1038/Sj.Bjc.6603923 |
0.428 |
|
| 2007 |
Ji JW, Mac Gabhann F, Popel AS. Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. American Journal of Physiology. Heart and Circulatory Physiology. 293: H3740-9. PMID 17890434 DOI: 10.1152/Ajpheart.00009.2007 |
0.704 |
|
| 2007 |
Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. The Journal of Biological Chemistry. 282: 37585-96. PMID 17848556 DOI: 10.1074/Jbc.M611500200 |
0.722 |
|
| 2007 |
Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circulation Research. 101: 948-56. PMID 17823371 DOI: 10.1161/Circresaha.107.160630 |
0.41 |
|
| 2007 |
Karagiannis ED, Popel AS. Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells. The International Journal of Biochemistry & Cell Biology. 39: 2314-23. PMID 17707681 DOI: 10.1016/J.Biocel.2007.06.018 |
0.783 |
|
| 2007 |
Chen K, Pittman RN, Popel AS. Vascular smooth muscle NO exposure from intraerythrocytic SNOHb: a mathematical model. Antioxidants & Redox Signaling. 9: 1097-110. PMID 17536957 DOI: 10.1089/Ars.2007.1594 |
0.3 |
|
| 2007 |
Karagiannis ED, Popel AS. Anti-angiogenic peptides identified in thrombospondin type I domains. Biochemical and Biophysical Research Communications. 359: 63-9. PMID 17531201 DOI: 10.1016/J.Bbrc.2007.05.041 |
0.776 |
|
| 2007 |
Mac Gabhann F, Popel AS. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophysical Chemistry. 128: 125-39. PMID 17442480 DOI: 10.1016/J.Bpc.2007.03.010 |
0.674 |
|
| 2007 |
Mac Gabhann F, Ji JW, Popel AS. Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Annals of Biomedical Engineering. 35: 982-94. PMID 17436110 DOI: 10.1007/S10439-007-9303-0 |
0.711 |
|
| 2007 |
Chen K, Popel AS. Vascular and perivascular nitric oxide release and transport: biochemical pathways of neuronal nitric oxide synthase (NOS1) and endothelial nitric oxide synthase (NOS3). Free Radical Biology & Medicine. 42: 811-22. PMID 17320763 DOI: 10.1016/J.Freeradbiomed.2006.12.007 |
0.3 |
|
| 2007 |
Mac Gabhann F, Demetriades AM, Deering T, Packer JD, Shah SM, Duh E, Campochiaro PA, Popel AS. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Annals of Biomedical Engineering. 35: 615-30. PMID 17277991 DOI: 10.1007/S10439-006-9238-X |
0.622 |
|
| 2007 |
Karagiannis ED, Popel AS. Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. Biochemical and Biophysical Research Communications. 354: 434-9. PMID 17239819 DOI: 10.1016/J.Bbrc.2006.12.231 |
0.747 |
|
| 2007 |
Mac Gabhann F, Ji JW, Popel AS. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. Journal of Applied Physiology (Bethesda, Md. : 1985). 102: 722-34. PMID 17038488 DOI: 10.1152/Japplphysiol.00800.2006 |
0.691 |
|
| 2007 |
Mac Gabhann F, Popel AS. Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. American Journal of Physiology. Heart and Circulatory Physiology. 292: H459-74. PMID 16980341 DOI: 10.1152/Ajpheart.00637.2006 |
0.708 |
|
| 2006 |
Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. Plos Computational Biology. 2: e180. PMID 17196035 DOI: 10.1371/Journal.Pcbi.0020180 |
0.719 |
|
| 2006 |
Mac Gabhann F, Ji JW, Popel AS. Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. Plos Computational Biology. 2: e127. PMID 17002494 DOI: 10.1371/Journal.Pcbi.0020127 |
0.71 |
|
| 2006 |
Qutub AA, Popel AS. A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha. Journal of Cell Science. 119: 3467-80. PMID 16899821 DOI: 10.1242/Jcs.03087 |
0.312 |
|
| 2006 |
Chen K, Popel AS. Theoretical analysis of biochemical pathways of nitric oxide release from vascular endothelial cells. Free Radical Biology & Medicine. 41: 668-80. PMID 16864000 DOI: 10.1016/J.Freeradbiomed.2006.05.009 |
0.361 |
|
| 2006 |
Kavdia M, Popel AS. Venular endothelium-derived NO can affect paired arteriole: a computational model. American Journal of Physiology. Heart and Circulatory Physiology. 290: H716-23. PMID 16155098 DOI: 10.1152/Ajpheart.00776.2005 |
0.366 |
|
| 2006 |
Karagiannis ED, Popel AS. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. Journal of Theoretical Biology. 238: 124-45. PMID 16005020 DOI: 10.1016/J.Jtbi.2005.05.020 |
0.738 |
|
| 2005 |
Popel AS, Johnson PC. Microcirculation and Hemorheology. Annual Review of Fluid Mechanics. 37: 43-69. PMID 21151769 DOI: 10.1146/Annurev.Fluid.37.042604.133933 |
0.34 |
|
| 2005 |
Mac Gabhann F, Yang MT, Popel AS. Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. Biochimica Et Biophysica Acta. 1746: 95-107. PMID 16257459 DOI: 10.1016/J.Bbamcr.2005.09.004 |
0.679 |
|
| 2005 |
Mac Gabhann F, Popel AS. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. American Journal of Physiology. Heart and Circulatory Physiology. 288: H2851-60. PMID 15708957 DOI: 10.1152/Ajpheart.01218.2004 |
0.712 |
|
| 2005 |
Gabhann FM, Ji JW, Popel AS. Computational Model of VEGF Spatial Distribution in Muscle and Pro-Angiogenic Cell Therapy Plos Computational Biology. DOI: 10.1371/Journal.Pcbi.0020127.Eor |
0.341 |
|
| 2004 |
Karagiannis ED, Popel AS. A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. The Journal of Biological Chemistry. 279: 39105-14. PMID 15252025 DOI: 10.1074/Jbc.M403627200 |
0.719 |
|
| 2004 |
Filion RJ, Popel AS. A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Annals of Biomedical Engineering. 32: 645-63. PMID 15171620 DOI: 10.1023/B:Abme.0000030231.88326.78 |
0.309 |
|
| 2004 |
Kavdia M, Popel AS. Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. Journal of Applied Physiology (Bethesda, Md. : 1985). 97: 293-301. PMID 15033959 DOI: 10.1152/Japplphysiol.00049.2004 |
0.353 |
|
| 2004 |
Tsoukias NM, Kavdia M, Popel AS. A theoretical model of nitric oxide transport in arterioles: frequency- vs. amplitude-dependent control of cGMP formation. American Journal of Physiology. Heart and Circulatory Physiology. 286: H1043-56. PMID 14592938 DOI: 10.1152/Ajpheart.00525.2003 |
0.342 |
|
| 2004 |
Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. American Journal of Physiology. Heart and Circulatory Physiology. 286: H153-64. PMID 12714333 DOI: 10.1152/Ajpheart.00254.2003 |
0.707 |
|
| 2003 |
Popel AS, Goldman D, Vadapalli A. Modeling of oxygen diffusion from the blood vessels to intracellular organelles. Advances in Experimental Medicine and Biology. 530: 485-95. PMID 14562744 DOI: 10.1007/978-1-4615-0075-9_46 |
0.3 |
|
| 2003 |
Kavdia M, Popel AS. Wall shear stress differentially affects NO level in arterioles for volume expanders and Hb-based O2 carriers. Microvascular Research. 66: 49-58. PMID 12826074 DOI: 10.1016/S0026-2862(03)00008-6 |
0.308 |
|
| 2002 |
Kavdia M, Tsoukias NM, Popel AS. Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. American Journal of Physiology. Heart and Circulatory Physiology. 282: H2245-53. PMID 12003834 DOI: 10.1152/Ajpheart.00972.2001 |
0.337 |
|
| 2000 |
Vadapalli A, Pittman RN, Popel AS. Estimating oxygen transport resistance of the microvascular wall. American Journal of Physiology. Heart and Circulatory Physiology. 279: H657-71. PMID 10924065 DOI: 10.1152/Ajpheart.2000.279.2.H657 |
0.309 |
|
| 1997 |
Cabel M, Meiselman HJ, Popel AS, Johnson PC. Contribution of red blood cell aggregation to venous vascular resistance in skeletal muscle. The American Journal of Physiology. 272: H1020-32. PMID 9124410 DOI: 10.1152/Ajpheart.1997.272.2.H1020 |
0.301 |
|
| 1994 |
Ellsworth ML, Ellis CG, Popel AS, Pittman RN. Role of Microvessels in Oxygen Supply to Tissue. News in Physiological Sciences : An International Journal of Physiology Produced Jointly by the International Union of Physiological Sciences and the American Physiological Society. 9: 119-123. PMID 29209101 DOI: 10.1152/Physiologyonline.1994.9.3.119 |
0.541 |
|
| 1989 |
Sharan M, Jones MD, Koehler RC, Traystman RJ, Popel AS. A compartmental model for oxygen transport in brain microcirculation. Annals of Biomedical Engineering. 17: 13-38. PMID 2919811 DOI: 10.1007/Bf02364271 |
0.312 |
|
| 1986 |
Levin M, Dawant B, Popel AS. Effect of dispersion of vessel diameters and lengths in stochastic networks. II. Modeling of microvascular hematocrit distribution. Microvascular Research. 31: 223-34. PMID 3702770 DOI: 10.1016/0026-2862(86)90036-1 |
0.307 |
|
| Show low-probability matches. |